HRP970699A2 - Method for the crystallisation of a tetrahydropyridin derivative and resulting crystalline forms - Google Patents

Method for the crystallisation of a tetrahydropyridin derivative and resulting crystalline forms

Info

Publication number
HRP970699A2
HRP970699A2 HR9615904A HRP970699A HRP970699A2 HR P970699 A2 HRP970699 A2 HR P970699A2 HR 9615904 A HR9615904 A HR 9615904A HR P970699 A HRP970699 A HR P970699A HR P970699 A2 HRP970699 A2 HR P970699A2
Authority
HR
Croatia
Prior art keywords
crystallisation
crystalline forms
resulting crystalline
tetrahydropyridin
derivative
Prior art date
Application number
HR9615904A
Inventor
Olivier Monnier
Original Assignee
Olivier Monnier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Olivier Monnier filed Critical Olivier Monnier
Publication of HRP970699A2 publication Critical patent/HRP970699A2/en
Publication of HRP970699B1 publication Critical patent/HRP970699B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HR970699A 1996-12-23 1997-12-22 Method for the crystallisation of a tetrahydropyridin derivative and resulting crystalline forms HRP970699B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9615904A FR2757543B1 (en) 1996-12-23 1996-12-23 PROCESS FOR THE CRYSTALLIZATION OF A TETRAHYDROPYRIDINE DERIVATIVE AND CRYSTALLINE FORMS THUS OBTAINED

Publications (2)

Publication Number Publication Date
HRP970699A2 true HRP970699A2 (en) 1998-10-31
HRP970699B1 HRP970699B1 (en) 2007-03-31

Family

ID=9499043

Family Applications (1)

Application Number Title Priority Date Filing Date
HR970699A HRP970699B1 (en) 1996-12-23 1997-12-22 Method for the crystallisation of a tetrahydropyridin derivative and resulting crystalline forms

Country Status (39)

Country Link
EP (1) EP0950050B1 (en)
JP (2) JP4499188B2 (en)
KR (1) KR100586670B1 (en)
CN (1) CN1129580C (en)
AR (1) AR009672A1 (en)
AT (1) ATE307802T1 (en)
AU (1) AU736697B2 (en)
BR (1) BR9714081A (en)
CA (1) CA2275596C (en)
CO (1) CO5070688A1 (en)
CZ (1) CZ296689B6 (en)
DE (1) DE69734460T2 (en)
DK (1) DK0950050T3 (en)
DZ (1) DZ2383A1 (en)
EE (1) EE04188B1 (en)
EG (1) EG21567A (en)
ES (1) ES2251038T3 (en)
FR (1) FR2757543B1 (en)
HK (1) HK1024002A1 (en)
HR (1) HRP970699B1 (en)
HU (1) HU227425B1 (en)
IL (1) IL129938A (en)
IN (1) IN186976B (en)
IS (1) IS2357B (en)
MY (1) MY118015A (en)
NO (1) NO312364B1 (en)
NZ (1) NZ336130A (en)
PL (1) PL190494B1 (en)
RS (1) RS49882B (en)
RU (1) RU2192416C2 (en)
SA (1) SA98180971B1 (en)
SI (1) SI0950050T1 (en)
SK (1) SK285088B6 (en)
TR (1) TR199901363T2 (en)
TW (1) TW518322B (en)
UA (1) UA60324C2 (en)
UY (1) UY24825A1 (en)
WO (1) WO1998028271A1 (en)
ZA (1) ZA9711576B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2757543B1 (en) * 1996-12-23 1999-04-02 Sanofi Sa PROCESS FOR THE CRYSTALLIZATION OF A TETRAHYDROPYRIDINE DERIVATIVE AND CRYSTALLINE FORMS THUS OBTAINED
FR2782082B3 (en) * 1998-08-05 2000-09-22 Sanofi Sa CRYSTALLINE FORMS OF (R) - (+) - N - [[3- [1-BENZOYL-3- (3,4- DICHLOROPHENYL) PIPERIDIN-3-YL] PROP-1-YL] -4-PHENYLPIPERIDIN-4 - YL] -N-METHYLACETAMIDE (OSANETANT) AND PROCESS FOR THE PREPARATION OF SAID COMPOUND
WO2011111856A1 (en) 2010-03-12 2011-09-15 株式会社日本触媒 Method for manufacturing a water-absorbing resin
EP2643294B1 (en) * 2011-04-15 2016-08-24 Emcure Pharmaceuticals Limited An improved rilpivirine process

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2531707A1 (en) * 1982-08-16 1984-02-17 Midy Spa SUBSTITUTED TRIFLUOROMETHYLPHENYLTETRAHYDROPYRIDINES WITH ANOREXIGENIC ACTIVITY, A PREPARATION PROCESS AND PHARMACEUTICAL COMPOSITIONS
FR2757543B1 (en) * 1996-12-23 1999-04-02 Sanofi Sa PROCESS FOR THE CRYSTALLIZATION OF A TETRAHYDROPYRIDINE DERIVATIVE AND CRYSTALLINE FORMS THUS OBTAINED

Also Published As

Publication number Publication date
WO1998028271A1 (en) 1998-07-02
EG21567A (en) 2001-12-31
CN1129580C (en) 2003-12-03
MY118015A (en) 2004-08-30
UY24825A1 (en) 1998-04-21
SK285088B6 (en) 2006-06-01
PL334256A1 (en) 2000-02-14
IN186976B (en) 2001-12-22
NZ336130A (en) 2001-01-26
HK1024002A1 (en) 2000-09-29
JP4499188B2 (en) 2010-07-07
RS49882B (en) 2008-08-07
NO993076D0 (en) 1999-06-22
EE9900264A (en) 2000-02-15
AU736697B2 (en) 2001-08-02
NO312364B1 (en) 2002-04-29
UA60324C2 (en) 2003-10-15
IS5076A (en) 1999-06-10
ES2251038T3 (en) 2006-04-16
IL129938A0 (en) 2000-02-29
DZ2383A1 (en) 2002-12-28
EP0950050B1 (en) 2005-10-26
KR20000069504A (en) 2000-11-25
KR100586670B1 (en) 2006-06-07
TR199901363T2 (en) 1999-08-23
HUP0001387A2 (en) 2000-09-28
JP2009197022A (en) 2009-09-03
DE69734460D1 (en) 2005-12-01
BR9714081A (en) 2000-05-09
JP2001507012A (en) 2001-05-29
SK82899A3 (en) 1999-12-10
EE04188B1 (en) 2003-12-15
PL190494B1 (en) 2005-12-30
CA2275596C (en) 2005-10-11
IL129938A (en) 2004-06-20
TW518322B (en) 2003-01-21
EP0950050A1 (en) 1999-10-20
SA98180971B1 (en) 2006-09-13
FR2757543A1 (en) 1998-06-26
IS2357B (en) 2008-04-15
DE69734460T2 (en) 2006-07-06
YU28999A (en) 2003-01-31
CA2275596A1 (en) 1998-07-02
RU2192416C2 (en) 2002-11-10
CZ296689B6 (en) 2006-05-17
AU5668498A (en) 1998-07-17
ZA9711576B (en) 1998-06-25
AR009672A1 (en) 2000-04-26
CO5070688A1 (en) 2001-08-28
CZ229299A3 (en) 1999-09-15
DK0950050T3 (en) 2006-01-23
SI0950050T1 (en) 2006-04-30
HUP0001387A3 (en) 2002-03-28
ATE307802T1 (en) 2005-11-15
FR2757543B1 (en) 1999-04-02
NO993076L (en) 1999-06-22
CN1241180A (en) 2000-01-12
HRP970699B1 (en) 2007-03-31
HU227425B1 (en) 2011-05-30

Similar Documents

Publication Publication Date Title
HK1023125A1 (en) Crystalline form of 4-Ä5-methyl-3-phenylisoxazol-4-ylÜbenzenesulfonamide
PL322501A1 (en) Method of obtaining 2-methyl-thiene-bezodiazepin and crystalline forms thereof
HUP9903454A3 (en) A crystalline form of cefditoren pivoxyl and process for the production of the same
HUP9601857A3 (en) N-benzyl-piperidine or tetrahydro-pyridine derivatives and processes for producing them
EP0944626A4 (en) Tropane derivatives and method for their synthesis
HUP9603377A3 (en) Crystalline maltitol composition and method for preparing the same
HUP9700536A3 (en) Crystalline vitamin d derivative
HUT74163A (en) New crystalline cepheme-acid-addicional salts and process for producing them
HK1000886A1 (en) A method for production of 3-formyl-tetrahydrofuran
HK1024002A1 (en) Method for the crystallisation of a tetrahydropyridin derivative and resulting crystalline forms
AU2567897A (en) Method and means for the production of a spring insert
AU5655698A (en) Suspension crystallization method
AU2274797A (en) Crystalline protease and method for producing same
HK1035530A1 (en) Novel crystal of depsipeptide derivative and a method for producing the same
IL130205A0 (en) Method for producing 1-phenyl-uracil derivatives
AU5655798A (en) Suspension crystallization method
GB9700086D0 (en) Method for producing ceramic superconductor single crystals
GB2319772B (en) 2-phenylazulene derivatives and a manufacturing method of these compounds
GB9621935D0 (en) Method for the control of crystallization
PL318306A1 (en) Method of obtaining crystalline cephuroxime ester
HUP9702472A3 (en) Process for producing allyl-amine derivative and salts thereof
PL325602A1 (en) Alternative crystalline form of thazophenelone
IL125283A0 (en) Process for the preparation of solvated crystalline forms of benzothiophene derivatives
HU9302156D0 (en) Method for producing 11beta-hydroxi-pregnane derivatives
SG33467A1 (en) A bislactone compound and a process for producing the same

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
PPPP Transfer of rights

Owner name: SANOFI-SYNTHELABO, FR

PNAN Change of the applicant name, address/residence

Owner name: SANOFI-AVENTIS, FR

B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20111217

Year of fee payment: 15

PBON Lapse due to non-payment of renewal fee

Effective date: 20121223